Cogent Biosciences presents preclinical data on JAK2 inhibitor at EHA

June 12, 2026 8:01 AM

Cogent Biosciences Inc. (NASDAQ: COGT) presented preclinical data for its JAK2 V617F inhibitor CGT1145 at the European Hematology Association Congress ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found